Fibrinogen Concentrate Safely Replaces Cryoprecipitate in Neonatal Cardiac Surgery
Anesthesia and Analgesia shared an insightful post on LinkedIn:
“When compared to cryoprecipitate, can fibrinogen concentrate adequately restore hemostasis and reduce postoperative thrombosis risk in neonates undergoing cardiac surgery with cardiopulmonary bypass (CPB)?
Patients who received fibrinogen concentrate CPB had similar ex vivo clot degradation rates throughout the immediate perioperative period with greater degradation at 24 hours postoperatively and received less post-CPB blood products with no increased risk of bleeding or thrombotic complications when compared to patients who received cryoprecipitate.
Given the increased risks associated with allogenic blood transfusions, our results suggest that fibrinogen concentrate may be a suitable alternative to achieve perioperative hemostasis in neonates undergoing cardiac surgery without increased risk of thrombotic or bleeding complications.”
Read the full article here.
Article: Effect of In Vivo Administration of Fibrinogen Concentrate Versus Cryoprecipitate on Ex Vivo Clot Degradation in Neonates Undergoing Cardiac Surgery
Authors: Laura A. Downey, Nina Moiseiwitsch, Kimberly Nellenbach, Yijin Xiang, Ashley C. Brown, Nina A.
Stay updated on the latest scientific advances in the field of clotting disorders with Hemostasis Today.
-
Aug 16, 2025, 14:00Iron Deficiency in Polycythemia Vera: William Aird Reveals JAK2-Driven Erythropoiesis as The Key Cause
-
Aug 15, 2025, 23:36Irene M Lang's Editorial on Getting Risk Assessment Right in Acute Pulmonary Embolism
-
Aug 15, 2025, 23:31Richard Buka: Many Improvements Needed in HIT Management
-
Aug 15, 2025, 23:29Cathy Harrison: Launching A Journal Club from EAHAD and WFH
-
Aug 15, 2025, 23:24PERT 2025 Symposium Session XIII: Expert Insights on CTEPH Diagnosis, Surgery and BPA Innovations - Join the Conversation
-
Aug 16, 2025, 16:33RPTH Journal: Dietmar Fries and Colleagues Explore Impact of Long-Distance Trail Running on Blood Markers
-
Aug 16, 2025, 16:15Josepha Clara Sedzro: First Cryo-EM Structure of the Coagulation Initiation Complex
-
Aug 16, 2025, 15:03Abdulla Damluji Highlights ASPREE Trial Update
-
Aug 16, 2025, 14:54Wolfgang Miesbach Highlights CRISPR-Cas9 Off-Target Safety in Human Genome Editing
-
Aug 16, 2025, 13:42LMWH Use for VTE Prophylaxis in COVID-19 Hospitalized Patients - Multicenter Data from China
-
Aug 16, 2025, 14:42Mark Crowther Honors Davide Matino for Leading Promising Hemophilia Trial at McMaster University
-
Aug 14, 2025, 10:28Impressive 95% Clot Removal in a VTE Case: Symphony16F and Symphony24F Catheters
-
Jul 28, 2025, 14:55HORIBA Decoding High Efficiency in Hematology Lab: Free Online Workshop
-
Jul 26, 2025, 17:56HIPEITHO Trial Achieves Remarkable Enrollment Milestone Across 72 Sites in the US and Europe
-
Jul 16, 2025, 15:04Toward Hemophilia Gene Therapy for All? Insights from Prof. Flora Peyvandi in Blood Advances
-
Aug 16, 2025, 14:18Christelle Orlando Highlights Breakthroughs in Thrombophilia Testing and AT Assays at ISTH 2025
-
Aug 15, 2025, 23:33Kacper Odziomek Excels in 2 Pharmacology Courses from Harvard Medical School
-
Aug 15, 2025, 03:44Call for Global Action on Bleeding Disorders from Baumann, Christoforou and Klamroth
-
Aug 14, 2025, 02:08Jordan Harry's Conversation on Cancer and Clot Risk with Thrombosis Canada
-
Aug 13, 2025, 15:50Will Parsons Honors National Leaders in Hematology: Drs. Fasipe, Powers and Tubman